AC Immune SA (ACIU) Form 6-K — Jun 30, 2026

AC Immune SA reported interim 12-month data from the Phase 1b/2 ABATE trial showing ACI-24 was generally safe and well-tolerated with no evidence of ARIA-E in the first three cohorts. Anti-Abeta antibody responses were detected at all dose levels, demonstrating a dose response across the 74 patients evaluated. Based on the results, the company initiated the AD4 cohort to test ACI-24 with an additional adjuvant designed to enhance immunogenicity and improve plaque removal.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.